RWT1RonaldTakvorianRonald Wayne Takvorian, M.D.42.36241700000000-71.0689370000000057524Takvorian, RonaldWayne617/724-1134Assistant Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson19344412Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman ASBritish journal of haematologyA phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8.Br J Haematol2009-03-30T00:00:002009A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.21355087Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BDBloodDoxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20.Blood2011-02-25T00:00:002011Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.16181848Graham BB, Mathisen DJ, Mark EJ, Takvorian RWThe Annals of thoracic surgeryPrimary pulmonary lymphoma. Ann Thorac Surg. 2005 Oct; 80(4):1248-53.Ann Thorac Surg2005-10-01T00:00:002005Primary pulmonary lymphoma.Authorship 1094462230207921Iyasere CA, Takvorian RW, Simeone FJ, Siegele BJThe New England journal of medicineCase 28-2018: A 39-Year-Old Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia. N Engl J Med. 2018 Sep 13; 379(11):1072-1081.N Engl J Med2018-09-13T00:00:002018Case 28-2018: A 39-Year-Old Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia.6491704Kaplan WD, Come SE, Takvorian RW, Laffin SM, Gelman RS, Weiss GR, Garnick MBJournal of clinical oncology : official journal of the American Society of Clinical OncologyPulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol. 1984 Nov; 2(11):1266-9.J Clin Oncol1984-11-01T00:00:001984Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion.Authorship 11345081330808634Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich JBloodClinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221.Blood2019-02-26T00:00:002019Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.D020258Disorders1702900.721373Neurotoxicity SyndromesD008223Disorders74618770.505761LymphomaD014740Chemicals & Drugs1293460.864966VidarabineD015451Disorders38716010.435941Leukemia, Lymphocytic, Chronic, B-CellD006689Disorders42014130.547135Hodgkin DiseaseMedicineNeurologyHematology/OncologyOncologyDana-Farber Cancer InstituteMassachusetts General HospitalMSD15MatthewDavidsMatthew Steven Davids, M.D.42.33789600000000-71.1072493000000074207Davids, MatthewAssociate Professor of MedicineJD61JorgDietrichJorg Dietrich, M.D.,Ph.D.42.36241700000000-71.0689370000000041197Dietrich, JorgAssociate Professor of NeurologyCMC37CesarCastroCesar Martin Castro, M.D.42.36241700000000-71.0689370000000085844Castro, CesarAssociate Professor of MedicineJDS50JacobSoumeraiJacob Drobnyk Soumerai, M.D.99789Soumerai, JacobAssistant Professor of MedicineJRB4JenniferBrownJennifer Ruth Brown, M.D., Ph.D.42.33789600000000-71.1072493000000035701Brown, JenniferWorthington and Margaret Collette Professor of Medicine in the Field of Hematologic OncologyEPH3EphraimHochbergEphraim Paul Hochberg, M.D.42.36241700000000-71.0689370000000037279Hochberg, EphraimAssistant Professor of MedicinePG92PaoloGhiaPaolo Ghia, M.D., Ph.D.114101Ghia, PaoloVisiting Professor of MedicineYAC1Yi-BinChenYi-Bin Albert Chen, M.D.42.36241700000000-71.0689370000000025663Chen, Yi-BinProfessor of MedicineAuthorship 116134610Authorship 11614762031208944Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JRThe Lancet. HaematologyIbrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428.Lancet Haematol2019-06-14T00:00:002019Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.31186274Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CMBloodBrentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 08 15; 134(7):606-613.Blood2019-06-11T00:00:002019Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.1123selected publications0.4770110.00154986125research areas0.8944460.0040805367coauthor of20.38442.1230160similar toJFG5JustinGainorJustin Franklin Gainor, M.D.42.36241700000000-71.0689370000000064512Gainor, JustinAssociate Professor of MedicineRPR1RachelRosovskyRachel Pam Rosovsky, M.D.42.36241700000000-71.0689370000000064221Rosovsky, RachelAssociate Professor of MedicineLSB7LawrenceBlaszkowskyLawrence Scott Blaszkowsky, M.D.42.36241700000000-71.0689370000000073258Blaszkowsky, LawrenceInstructor in MedicineJSA6JeremyAbramsonJeremy S. Abramson, M.D.42.36241700000000-71.0689370000000077954Abramson, JeremyAssociate Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Instructor in MedicineInstructor in Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of MedicineAuthorship 1428457935073571Haydu JE, Maron JS, Redd RA, Gallagher KME, Fischinger S, Barnes JA, Hochberg EP, Johnson PC, Takvorian RW, Katsis K, Portman D, Ruiters J, Sechio S, Devlin M, Regan C, Blumenthal KG, Banerji A, Judd AD, Scorsune KJ, McGree BM, Sherburne MM, Lynch JM, Weitzman JI, Lei M, Kotton CN, Dighe AS, Maus MV, Alter G, Abramson JS, Soumerai JDBlood advancesHumoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv. 2022 03 22; 6(6):1671-1683.Blood Adv2022-03-22T00:00:002022Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.true1Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic OncologyWorthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncologytrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Visiting Professor of MedicineVisiting Professor of MedicineAuthorship 1500806236174642Soumerai JD, Takvorian RW, Sohani AR, Abramson JS, Ferry JAThe Lancet. HaematologyVenetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. Lancet Haematol. 2022 10; 9(10):e796.Lancet Haematol2022-10-01T00:00:002022Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia.true1Professor of MedicineProfessor of MedicineAuthorship 15678182437402650Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich JNeuro-oncologyNeurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol. 2023 12 08; 25(12):2239-2249.Neuro Oncol2023-12-08T00:00:002023Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.Authorship 15835461137756532Karmali R, Abramson JS, Stephens DM, Barnes J, Winter JN, Ma S, Gao J, Kaplan J, Petrich AM, Hochberg E, Takvorian T, Mi X, Nelson V, Gordon LI, Pro BBlood advancesIbrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Adv. 2023 12 12; 7(23):7361-7368.Blood Adv2023-12-12T00:00:002023Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.Authorship 1594124537795759Ababneh HS, Ng AK, Abramson JS, Soumerai JD, Takvorian RW, Frigault MJ, Patel CGHematological oncologyMetabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma. Hematol Oncol. 2024 Jan; 42(1):e3231.Hematol Oncol2023-10-05T00:00:002023Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.true1Associate Professor of NeurologyAssociate Professor of NeurologyAuthorship 16178472038163317Ahn IE, Brander DM, Ren Y, Zhou Y, Tyekucheva S, Walker HA, Black R, Montegaard J, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng SY, Crombie J, Fisher DC, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Brown JR, Davids MSBlood advancesFive-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood Adv. 2024 Feb 27; 8(4):832-841.Blood Adv2024-02-27T00:00:002024Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.Authorship 670295223289359Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EPLeukemia & lymphomaOral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma. 2013 Sep; 54(9):1915-20.Leuk Lymphoma2013-01-30T00:00:002013Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.JC445JorgeCastilloJorge Castillo, M.D.121919Castillo, JorgeAssociate Professor of MedicineAuthorship 34843812Authorship 715214723734654Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP, Abramson JSLeukemia & lymphomaTreatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014 Mar; 55(3):538-43.Leuk Lymphoma2013-07-29T00:00:002013Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.Authorship 2915193Authorship 5428062Authorship 779149425238446Cohen JM, Nazarian RM, Ferry JA, Takvorian RW, Carter JBThe American Journal of dermatopathologyRare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature. Am J Dermatopathol. 2015 Jan; 37(1):e1-4.Am J Dermatopathol2015-01-01T00:00:002015Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.Authorship 824734Authorship 4112567Authorship 2735848Authorship 5242115Authorship 8261531526009261Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, Armand P, Barnes J, Brown J, Cutler C, El-Jawahri A, Ho VT, Hochberg E, McAfee S, Takvorian R, Spitzer TR, Antin JH, Soiffer R, Jacobsen EBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8.Biol Blood Marrow Transplant2015-05-22T00:00:002015Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.Authorship 695704Authorship 32390032Assistant Professor1Associate Professor0Full Professor4Instructor55 Fruit StMassachusetts General HospitalHem/Onc Cox 2 20155 Fruit StBoston02114MA7471113Kaplan WD, Ensminger WD, Come SE, Smith EH, D'Orsi CJ, Levin DC, Takvorian RW, Steele GDCancer treatment reportsRadionuclide angiography to predict patient response to hepatic artery chemotherapy. Cancer Treat Rep. 1980; 64(12):1217-22.Cancer Treat Rep1980-01-01T00:00:001980Radionuclide angiography to predict patient response to hepatic artery chemotherapy.11157025Backstrand KH, Ng AK, Takvorian RW, Jones EL, Fisher DC, Molnar-Griffin BJ, Silver B, Tarbell NJ, Mauch PMJournal of clinical oncology : official journal of the American Society of Clinical OncologyResults of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease. J Clin Oncol. 2001 Feb 01; 19(3):736-41.J Clin Oncol2001-02-01T00:00:002001Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease.21844421Lee LN, Hasserjian RP, Faquin WC, Takvorian RW, Rocco JWArchives of otolaryngology--head & neck surgeryPathology quiz case 1. Diffuse large B-cell lymphoma (DLBCL) of the thyroid. Arch Otolaryngol Head Neck Surg. 2011 Aug; 137(8):829; author reply 832-3.Arch Otolaryngol Head Neck Surg2011-08-01T00:00:002011Pathology quiz case 1. Diffuse large B-cell lymphoma (DLBCL) of the thyroid.20309431Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani ARJournal of hematopathologyRare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop. 2009 Aug 20; 2(4):237-44.J Hematop2009-08-20T00:00:002009Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls.6092092Stahel RA, Takvorian RW, Skarin AT, Canellos GPEuropean journal of cancer & clinical oncologyAutologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol. 1984 Oct; 20(10):1233-8.Eur J Cancer Clin Oncol1984-10-01T00:00:001984Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature.